{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:21:01Z","timestamp":1793859661346,"version":"4.6.1"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T00:00:00Z","timestamp":1571356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Alzheimer's Association (USA) and Brain Canada","id":[{"id":"https:\/\/ror.org\/0375f4d26","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41380-019-0536-8","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T08:39:07Z","timestamp":1571387947000},"page":"5532-5541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["The complement cascade in Alzheimer\u2019s disease: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6679-4067","authenticated-orcid":false,"given":"Saffire H.","family":"Krance","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Yuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-6022","authenticated-orcid":false,"given":"Huiyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Toufighi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Pakosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0030-8908","authenticated-orcid":false,"given":"Walter","family":"Swardfager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,18]]},"reference":[{"key":"536_CR1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368:387\u2013403.","journal-title":"Lancet"},{"key":"536_CR2","unstructured":"Prince MJ. World Alzheimer Report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends. London, UK: Alzheimer\u2019s Disease International; 2015."},{"key":"536_CR3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet. 2009;41:1088.","journal-title":"Nat Genet"},{"key":"536_CR4","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"J-C Lambert","year":"2009","unstructured":"Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet. 2009;41:1094.","journal-title":"Nat Genet"},{"key":"536_CR5","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/npp.2015.232","volume":"41","author":"D-F Zhang","year":"2016","unstructured":"Zhang D-F, Li J, Wu H, Cui Y, Bi R, Zhou H-J, et al. CFH variants affect structural and functional brain changes and genetic risk of Alzheimer\u2019s disease. Neuropsychopharmacology. 2016;41:1034\u201345.","journal-title":"Neuropsychopharmacology"},{"key":"536_CR6","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.molimm.2011.04.003","volume":"48","author":"R Veerhuis","year":"2011","unstructured":"Veerhuis R, Nielsen HM, Tenner AJ. Complement in the brain. Mol Immunol. 2011;48:1592\u2013603.","journal-title":"Mol Immunol"},{"key":"536_CR7","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1749-6632.2003.tb03138.x","volume":"992","author":"J Van Beek","year":"2003","unstructured":"Van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system. Ann NY Acad Sci. 2003;992:56\u201371.","journal-title":"Ann NY Acad Sci"},{"key":"536_CR8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00281-017-0662-9","volume":"40","author":"BP Morgan","year":"2018","unstructured":"Morgan BP. Complement in the pathogenesis of Alzheimer\u2019s disease. Semin Immunopathol. 2018;40:113\u201324.","journal-title":"Semin Immunopathol"},{"key":"536_CR9","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. Br Med J. 2009;339:b2700.","journal-title":"Br Med J"},{"key":"536_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135\u2013135.","journal-title":"BMC Med Res Methodol"},{"key":"536_CR11","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from https:\/\/www.training.cochrane.org\/handbook.","DOI":"10.1002\/9781119536604"},{"key":"536_CR12","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1002\/sim.3427","volume":"27","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, White IR, Anzures\u2010Cabrera J. Meta\u2010analysis of skewed data: combining results reported on log\u2010transformed or raw scales. Stat Med. 2008;27:6072\u201392.","journal-title":"Stat Med"},{"key":"536_CR13","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Br Med J. 2011;343:d5928.","journal-title":"Br Med J"},{"key":"536_CR14","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. Ottawa, Canada: The Ottawa Health Research Institute; 2000. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.htm."},{"key":"536_CR15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1536867X0800800102","volume":"8","author":"RJ Harris","year":"2008","unstructured":"Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC. Metan: fixed- and random-effects meta-analysis. Stata J. 2008;8:3\u201328.","journal-title":"Stata J"},{"key":"536_CR16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jclinepi.2010.08.010","volume":"64","author":"R Fu","year":"2011","unstructured":"Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. J Clin Epidemiol. 2011;64:1187\u201397.","journal-title":"J Clin Epidemiol"},{"key":"536_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"536_CR18","unstructured":"Wickham H. ggplot2: elegant graphics for data analysis. New York: Springer-Verlag."},{"key":"536_CR19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/alzrt266","volume":"6","author":"JB Toledo","year":"2014","unstructured":"Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. Alzheimers Res Ther. 2014;6:36.","journal-title":"Alzheimers Res Ther"},{"key":"536_CR20","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbi.2016.07.148","volume":"58","author":"A Swanson","year":"2016","unstructured":"Swanson A, Willette AA. Neuronal pentraxin 2 predicts medial temporal atrophy and memory decline across the Alzheimer\u2019s disease spectrum. Brain Behav Immun. 2016;58:201\u20138.","journal-title":"Brain Behav Immun"},{"key":"536_CR21","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40478-016-0339-y","volume":"4","author":"LW Bonham","year":"2016","unstructured":"Bonham LW, Desikan RS, Yokoyama JS. The relationship between complement factor C3, APOE \u03b54, amyloid and tau in Alzheimer\u2019s disease. Acta Neuropathol Commun. 2016;4:65.","journal-title":"Acta Neuropathol Commun"},{"key":"536_CR22","doi-asserted-by":"crossref","first-page":"e44260","DOI":"10.1371\/journal.pone.0044260","volume":"7","author":"SJ Kiddle","year":"2012","unstructured":"Kiddle SJ, Thambisetty M, Simmons A, Riddoch-Contreras J, Hye A, Westman E, et al. Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS ONE. 2012;7:e44260.","journal-title":"PLoS ONE"},{"key":"536_CR23","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/archneurol.2012.1070","volume":"69","author":"HD Soares","year":"2012","unstructured":"Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol. 2012;69:1310\u20137.","journal-title":"Arch Neurol"},{"key":"536_CR24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fnagi.2018.00390","volume":"10","author":"BC Riedel","year":"2018","unstructured":"Riedel BC, Daianu M, Ver Steeg G, Mezher A, Salminen LE, Galstyan A, et al. Uncovering biologically coherent peripheral signatures of health and risk of Alzheimer\u2019s disease in the aging brain. Front Aging Neurosci. 2018;10:390.","journal-title":"Front Aging Neurosci"},{"key":"536_CR25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00685397","volume":"57","author":"P Eikelenboom","year":"1982","unstructured":"Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. Acta Neuropathol. 1982;57:239\u201342.","journal-title":"Acta Neuropathol"},{"key":"536_CR26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF00687336","volume":"63","author":"T Ishii","year":"1984","unstructured":"Ishii T, Haga S. Immuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol. 1984;63:296\u2013300.","journal-title":"Acta Neuropathol"},{"key":"536_CR27","doi-asserted-by":"crossref","unstructured":"Ishii T, Haga S, Kametani F. Presence of immunoglobulins and complements in the amyloid plaques in the brain of patients with Alzheimer\u2019s disease. In: Pouplard-Barthelaix A, Emile J, Christen Y, editors. Immunology and Alzheimer\u2019s disease: research and perspectives in Alzheimer\u2019s disease; Berlin, Heidelberg: Springer Berlin Heidelberg; 1988. p. 17\u201329.","DOI":"10.1007\/978-3-642-46634-2_3"},{"key":"536_CR28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0006-8993(92)90071-G","volume":"579","author":"PL McGeer","year":"1992","unstructured":"McGeer PL, Kawamata T, Walker DG. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 1992;579:337\u201341.","journal-title":"Brain Res"},{"key":"536_CR29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0006-8993(97)00849-4","volume":"769","author":"K Terai","year":"1997","unstructured":"Terai K, Walker DG, McGeer EG, McGeer PL. Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res. 1997;769:385\u201390.","journal-title":"Brain Res"},{"key":"536_CR30","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00202265","volume":"73","author":"B Fischer","year":"1995","unstructured":"Fischer B, Schmoll H, Platt D, Popa-Wagner A, Riederer P, Bauer J. Complement C1q and C3 mRNA expression in the frontal cortex of Alzheimer\u2019s patients. J Mol Med. 1995;73:465\u201371.","journal-title":"J Mol Med"},{"key":"536_CR31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0197-4580(92)90086-D","volume":"13","author":"SA Johnson","year":"1992","unstructured":"Johnson SA, Lampert-Etchells M, Pasinetti GM, Rozovsky I, Finch CE. Complement mRNA in the mammalian brain: responses to Alzheimer\u2019s disease and experimental brain lesioning. Neurobiol Aging. 1992;13:641\u20138.","journal-title":"Neurobiol Aging"},{"key":"536_CR32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0006-8993(97)00850-0","volume":"769","author":"Y Shen","year":"1997","unstructured":"Shen Y, Li R, McGeer EG, McGeer PL. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769:391\u20135.","journal-title":"Brain Res"},{"key":"536_CR33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02890024","volume":"56","author":"P Eikelenboom","year":"1989","unstructured":"Eikelenboom P, Hack CE, Rozemuller JM, Stam FC. Complement activation in amyloid plaques in Alzheimer\u2019s dementia. Virchows Arch B Cell Pathol Incl Mol Pathol. 1989;56:259.","journal-title":"Virchows Arch B Cell Pathol Incl Mol Pathol"},{"key":"536_CR34","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0304-3940(89)90843-4","volume":"107","author":"PL McGeer","year":"1989","unstructured":"McGeer PL, Akiyama H, Itagaki S, McGeer EG. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989;107:341\u20136.","journal-title":"Neurosci Lett"},{"key":"536_CR35","doi-asserted-by":"crossref","first-page":"13460","DOI":"10.1523\/JNEUROSCI.1333-13.2013","volume":"33","author":"AH Stephan","year":"2013","unstructured":"Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, et al. A dramatic increase of C1q protein in the CNS during normal aging. J Neurosci. 2013;33:13460\u201374.","journal-title":"J Neurosci"},{"key":"536_CR36","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-179","volume":"9","author":"DH Cribbs","year":"2012","unstructured":"Cribbs DH, Berchtold NC, Perreau V, Coleman PD, Rogers J, Tenner AJ, et al. Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. J Neuroinflammation. 2012;9:179.","journal-title":"J Neuroinflammation"},{"key":"536_CR37","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1073\/pnas.89.21.10016","volume":"89","author":"J Rogers","year":"1992","unstructured":"Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1992;89:10016.","journal-title":"Proc Natl Acad Sci USA"},{"key":"536_CR38","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.4049\/jimmunol.152.10.5050","volume":"152","author":"H Jiang","year":"1994","unstructured":"Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol. 1994;152:5050.","journal-title":"J Immunol"},{"key":"536_CR39","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.4049\/jimmunol.167.11.6374","volume":"167","author":"P Tacnet-Delorme","year":"2001","unstructured":"Tacnet-Delorme P, Chevallier S, Arlaud GJ. \u03b2-Amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A\u03b2 on the C1q globular regions. J Immunol. 2001;167:6374.","journal-title":"J Immunol"},{"key":"536_CR40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOT.0b013e32834253c7","volume":"16","author":"TW Du Clos","year":"2011","unstructured":"Du Clos TW, Mold C. Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fc\u03b3 receptors. Curr Opin Organ Transpl. 2011;16:15\u201320.","journal-title":"Curr Opin Organ Transpl"},{"key":"536_CR41","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1084\/jem.188.3.431","volume":"188","author":"BM Bradt","year":"1998","unstructured":"Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer\u2019s disease \u03b2-peptide. J Exp Med. 1998;188:431.","journal-title":"J Exp Med"},{"key":"536_CR42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/187152809788681038","volume":"8","author":"Q Peng","year":"2009","unstructured":"Peng Q, Li K, Sacks SH, Zhou W. The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets. 2009;8:236\u201346.","journal-title":"Inflamm Allergy Drug Targets"},{"key":"536_CR43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000371423","volume":"7","author":"SR Barnum","year":"2015","unstructured":"Barnum SR. C4a: an anaphylatoxin in name only. J Innate Immun. 2015;7:333\u20139.","journal-title":"J Innate Immun"},{"key":"536_CR44","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1073\/pnas.1707364114","volume":"114","author":"H Wang","year":"2017","unstructured":"Wang H, Ricklin D, Lambris JD. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc Natl Acad Sci USA. 2017;114:10948\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"536_CR45","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.cell.2007.10.036","volume":"131","author":"B Stevens","year":"2007","unstructured":"Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164\u201378.","journal-title":"Cell"},{"key":"536_CR46","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1126\/science.aad8373","volume":"352","author":"S Hong","year":"2016","unstructured":"Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712\u20136.","journal-title":"Science"},{"key":"536_CR47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0169-328X(00)00149-2","volume":"81","author":"R Strohmeyer","year":"2000","unstructured":"Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer\u2019s disease brain. Brain Res Mol Brain Res. 2000;81:7\u201318.","journal-title":"Brain Res Mol Brain Res"},{"key":"536_CR48","doi-asserted-by":"crossref","unstructured":"Woody SK, Zhao L Clusterin (APOJ) in Alzheimer\u2019s disease: an old molecule with a new role. In Update on Dementia. London, UK; 2016. IntechOpen.","DOI":"10.5772\/64233"},{"key":"536_CR49","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1096\/fj.06-7986com","volume":"21","author":"JJ Yerbury","year":"2007","unstructured":"Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 2007;21:2312\u201322.","journal-title":"FASEB J"},{"key":"536_CR50","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0006-8993(94)91640-3","volume":"645","author":"S Itagaki","year":"1994","unstructured":"Itagaki S, Akiyama H, Saito H, McGeer PL. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer\u2019s disease. Brain Res. 1994;645:78\u201384.","journal-title":"Brain Res"},{"key":"536_CR51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s004019570001","volume":"91","author":"R Veerhuis","year":"1995","unstructured":"Veerhuis R, Janssen I, Hack CE, Eikelenboom P. Early complement components in Alzheimer\u2019s disease brains. Acta Neuropathol. 1995;91:53\u201360.","journal-title":"Acta Neuropathol"},{"key":"536_CR52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/BF00192116","volume":"426","author":"R Veerhuis","year":"1995","unstructured":"Veerhuis R, van der Valk P, Janssen I, Zhan SS, Eikelenboom P, Van Nostrand WE. Complement activation in amyloid plaques in Alzheimer\u2019s disease brains does not proceed further than C3. Virchows Arch. 1995;426:603\u201310.","journal-title":"Virchows Arch"},{"key":"536_CR53","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0197-4580(97)00042-0","volume":"18","author":"S Webster","year":"1997","unstructured":"Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, et al. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer\u2019s disease. Neurobiol Aging 1997;18:415\u201321.","journal-title":"Neurobiol Aging"},{"key":"536_CR54","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/01.wad.0000165506.60370.94","volume":"19","author":"H Zanjani","year":"2005","unstructured":"Zanjani H, Finch CE, Kemper C, Atkinson J, McKeel D, Morris JC, et al. Complement activation in very early Alzheimer disease. Alzheimer Dis Assoc Disord. 2005;19:55\u201366.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"536_CR55","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cei.12952","volume":"188","author":"R Lubbers","year":"2017","unstructured":"Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production of complement components by cells of the immune system. Clin Exp Immunol. 2017;188:183\u201394.","journal-title":"Clin Exp Immunol"},{"key":"536_CR56","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.jalz.2018.07.223","volume":"14","author":"KL Rasmussen","year":"2018","unstructured":"Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R, Nielsen SF. An updated Alzheimer hypothesis: complement C3 and risk of Alzheimer\u2019s disease\u2014a cohort study of 95,442 individuals. Alzheimers Dement. 2018;14:1589\u2013601.","journal-title":"Alzheimers Dement"},{"key":"536_CR57","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1523\/JNEUROSCI.0829-08.2008","volume":"28","author":"M Maier","year":"2008","unstructured":"Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA. Complement C3-deficiency leads to accelerated AB plaque deposition and neurodegeneration, and modulation of the microglia\/macrophage phenotype in APP transgenic mice. J Neurosci. 2008;28:6333\u201341.","journal-title":"J Neurosci"},{"key":"536_CR58","doi-asserted-by":"crossref","first-page":"eaaf6295","DOI":"10.1126\/scitranslmed.aaf6295","volume":"9","author":"Q Shi","year":"2017","unstructured":"Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP\/PS1 mice. Sci Trans Med. 2017;9:eaaf6295.","journal-title":"Sci Trans Med"},{"key":"536_CR59","doi-asserted-by":"crossref","first-page":"2949.e5","DOI":"10.1016\/j.neurobiolaging.2012.07.001","volume":"33","author":"L-N Hazrati","year":"2012","unstructured":"Hazrati L-N, Van Cauwenberghe C, Brooks PL, Brouwers N, Ghani M, Sato C, et al. Genetic association of CR1 with Alzheimer\u2019s disease: a tentative disease mechanism. Neurobiol Aging. 2012;33:2949.e5\u20132949.e12.","journal-title":"Neurobiol Aging"},{"key":"536_CR60","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.4049\/jimmunol.156.6.2247","volume":"156","author":"P Gasque","year":"1996","unstructured":"Gasque P, Chan P, Mauger C, Schouft MT, Singhrao S, Dierich MP, et al. Identification and characterization of complement C3 receptors on human astrocytes. J Immunol. 1996;156:2247.","journal-title":"J Immunol"},{"key":"536_CR61","first-page":"1247","volume":"79","author":"SK Singhrao","year":"1999","unstructured":"Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Investig. 1999;79:1247\u201359.","journal-title":"Lab Investig"},{"key":"536_CR62","doi-asserted-by":"crossref","first-page":"e0149792","DOI":"10.1371\/journal.pone.0149792","volume":"11","author":"MI Fonseca","year":"2016","unstructured":"Fonseca MI, Chu S, Pierce AL, Brubaker WD, Hauhart RE, Mastroeni D, et al. Analysis of the putative role of CR1 in Alzheimer\u2019s disease: genetic association, expression and function. PLoS One. 2016;11:e0149792.","journal-title":"PLoS One"},{"key":"536_CR63","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jalz.2018.04.003","volume":"2018","author":"JU Johansson","year":"2018","unstructured":"Johansson JU, Brubaker WD, Javitz H, Bergen AW, Nishita D, Trigunaite A, et al. Peripheral complement interactions with amyloid \u03b2 peptide in Alzheimer\u2019s disease: polymorphisms, structure, and function of complement receptor 1. Alzheimers Dement. 2018;2018:1438\u201349.","journal-title":"Alzheimers Dement"},{"key":"536_CR64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1034\/j.1600-065X.2001.1800109.x","volume":"180","author":"DJ Birmingham","year":"2001","unstructured":"Birmingham DJ, Hebert LACR1. and CR1-like: the primate immune adherence receptors. Immunol Rev. 2001;180:100\u201311.","journal-title":"Immunol Rev"},{"key":"536_CR65","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.neurobiolaging.2005.09.043","volume":"27","author":"J Rogers","year":"2006","unstructured":"Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, et al. Peripheral clearance of amyloid \u03b2 peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging. 2006;27:1733\u20139.","journal-title":"Neurobiol Aging"},{"key":"536_CR66","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3233\/JAD-160025","volume":"53","author":"S Kang","year":"2016","unstructured":"Kang S, Jeong H, Baek J-H, Lee S-J, Han S-H, Jin Cho H, et al. PiB-PET imaging-based serum proteome profiles predict mild cognitive impairment and Alzheimer\u2019s disease. J Alzheimers Dis. 2016;53:1563\u201376.","journal-title":"J Alzheimers Dis"},{"key":"536_CR67","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0006-8993(96)01324-8","volume":"749","author":"PL McGeer","year":"1997","unstructured":"McGeer PL, Walker DG, Pitas RE, Mahley RW, McGeer EG. Apolipoprotein E4 (ApoE4) but not ApoE3 or ApoE2 potentiates \u03b2-amyloid protein activation of complement in vitro. Brain Res. 1997;749:135\u20138.","journal-title":"Brain Res"},{"key":"536_CR68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12987-018-0113-6","volume":"15","author":"SB Hladky","year":"2018","unstructured":"Hladky SB, Barrand MA. Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood\u2013brain barrier. Fluids Barriers CNS. 2018;15:30.","journal-title":"Fluids Barriers CNS"},{"key":"536_CR69","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1084\/jem.20171406","volume":"214","author":"A Montagne","year":"2017","unstructured":"Montagne A, Zhao Z, Zlokovic B. Alzheimer\u2019s disease: a matter of blood\u2013brain barrier dysfunction? J Exp Med. 2017;214:3151\u201369.","journal-title":"J Exp Med"},{"key":"536_CR70","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1471-4159.2007.05012.x","volume":"104","author":"K Pisalyaput","year":"2008","unstructured":"Pisalyaput K, Tenner AJ. Complement component C1q inhibits \u03b2-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem. 2008;104:696\u2013707.","journal-title":"J Neurochem"},{"key":"536_CR71","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1006\/bbrc.1995.2852","volume":"217","author":"S Webster","year":"1995","unstructured":"Webster S, Glabe C, Rogers J. Multivalent binding of complement protein C1q to the amyloid \u03b2-peptide (A\u03b2) promotes the nucleation phase of A\u03b2 aggregation. Biochem Biophys Res Commun. 1995;217:869\u201375.","journal-title":"Biochem Biophys Res Commun"},{"key":"536_CR72","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1021600212829","volume":"28","author":"KW Boyett","year":"2003","unstructured":"Boyett KW, DiCarlo G, Jantzen PT, Jackson J, O\u2019Leary C, Wilcock D, et al. Increased fibrillar \u03b2-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochem Res. 2003;28:83\u201393.","journal-title":"Neurochem Res"},{"key":"536_CR73","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0006-8993(98)00346-1","volume":"796","author":"Y Shen","year":"1998","unstructured":"Shen Y, Sullivan T, Lee C-M, Meri S, Shiosaki K, Lin CW. Induced expression of neuronal membrane attack complex and cell death by Alzheimer\u2019s \u03b2-amyloid peptide. Brain Res. 1998;796:187\u201397.","journal-title":"Brain Res"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0536-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0536-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T02:05:02Z","timestamp":1721873102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-019-0536-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,18]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1038\/s41380-019-0536-8","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,18]]},"assertion":[{"value":"31 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}